DOCSLIB.ORG

Neutron Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neutron Therapy Medical applications penetration depths and decrease for R&D investment, and this should skin exposure. Alternatively, electro­ lead to smaller hospital space re­ Therapy therapy can be used with different quirements, lower operating costs, energies for lower and variable and elimination of external data s life expectancy steadily im­ penetration depths - approximately handling, resulting in simpler and A proves, the incidence of cancer 0.5 cm per MeV. In this way surface more cost effective clinical proce­ also increases as the population tissue may be treated without affect­ dures. ages. Up to 50% of cancer patients ing deeper and more critical anatomi­ undergo radiotherapy - a form of cal regions. From D Tronc, General Electric protracted biological surgery by This type of linac, 1 to 2 metres Medical Systems, Paris selective sterilization of malignant long, is mounted parallel to the cells. patient with a bending magnet to direct the beam to the radiotherapy system, which includes the target, Neutron therapy X-ray radiotherapy thick movable collimator jaws, a beam field equalizer, dose rate and tandard radiotherapy uses X- he most common form of radio optical field simulation and energy S rays or electrons which have low T therapy is X-ray therapy, where a controls. LET (linear energy transfer); in beam of photons or their parent There are over 2000 accelerator- contrast, particles such as neutrons electrons break down hydrogen based X-ray treatment units world­ with high LET have different bonds within the body's cells and wide. Western countries have up to radiobiological responses. In the late remove certain DNA information two units per million population, 1960s, clinical trials by Mary Catterall necessary for cell multiplication. whereas in developing countries at the Hammersmith Hospital in This process can eradicate malignant such as Bangladesh, the density is London indicated that fast neutron cells leading to complete recovery, to only one per 100 million. radiation had clinical advantages for the remission of some cancers, or at Several major medical equipment certain malignant tumours. least to a degree of pain relief. companies manufacture X-ray Following these early clinical trials, The radiotherapy instrument is therapy systems - General Electric, several cyclotron facilities were built usually an electron linac, and the Mitsubishi, Philips, Siemens and in the 1980s for fast neutron therapy, electrons are used either directly in Varian. In this crowded marketplace for example at the University of 'electrotherapy' for some 10% of where the useful lifespan of ma­ Washington, Seattle, and at UCLA. patients, or the electrons bombard a chines exceeds 10 years, purchase Most of these newer machines use conversion target creating a broad prices are less than $1 million per extracted cyclotron proton beams in beam of high energy photons or unit. the range 42 to 66 MeV with beam 'penetration X-rays'. X-ray therapy remains the most intensities of 15 to 60 microamps. The simplest machine consists of common and cheapest form of The proton beams are transported to several accelerating sections at accelerator therapy. Ongoing techni­ dedicated therapy rooms, where around 3 GHz, accelerating electrons cal developments aim to achieve neutrons are produced from beryllium to 6 MeV; a cooled tungsten target is better matching of dose delivery to targets. used to produce a 4 Gray/min X-ray tumour volume; multileaf collimators Second-generation clinical trials field which can be collimated into a shape the X-ray field to the biomedi­ showed that accurate neutron beam rectangular shape at the patient cal target, and portal imaging from delivery to the tumour site is more position. This tiny linac is mounted behind the patient can control posi­ critical than for photon therapy. inside a rotating isocentric gantry tioning and dose delivery. In order to achieve precise beam above the patient who must remain Combined compact X-ray sources geometries, the extracted proton perfectly still. Several convergent are being developed with both beams have to be transported beams can also be used to increase treatment and realtime dosimetry through a gantry which can rotate the delivered dose. control, incorporating CT scanning around the patient and deliver beams More sophisticated accelerators into one single device. Integrated from any angle; also the neutron operate at up to 18 MeV to increase diagnosis and therapy is the direction beam outline ("field shape") must be CERN Courier, July/August 1995 7 Medical applications In the late 1960s, clinical trials showed that fast neutron radiation had clinical advantages for the treatment of certain cancers. In modern neutron therapy centres, protons from a cyclotron bombard a beryllium target to generate a collimated beam of neutrons. (Photo University of Washington, Seattle) with other users, particularly since beam-time for an actual therapy run is only a few minutes but involves considerable set-up periods between runs; radioisotope or PET production may be performed concurrently with neutron therapy. At present there are about a dozen neutron therapy facilities worldwide, but due to limitations of fixed beams, low energies or low intensities, only a few of these can deliver the precision beams required . Clinical results with neutron therapy are very encouraging for certain specific tumour sites; for salivary gland tumours neutron therapy is considered the treatment of choice. Other promising areas of clinical research are advanced adeno­ carcinoma of the prostrate, some adjusted to extremely irregular scanners and radiation simulators head and neck tumours, some lung shapes using a flexible collimation must be made available. Neutron cancers and sarcomas of bone and system. therapy is usually performed only in soft tissue. A therapy procedure has to be radiation oncology departments of For future neutron therapy systems appropriately organized, with physi­ major medical centres. there is a choice between two basic cians, radiotherapists, nurses, However neutron therapy is much designs: medical physicists and other staff in more expensive than conventional - a small cyclotron with internal attendance; other specialized photon or electron therapy. Often the target, mounted directly on the equipment, such as CT or MRI cyclotron operation has to be shared therapy gantry in a very compact machine dedicated to neutron therapy (such as that developed for Harper Hospital in Detroit using a superconducting deuteron cyclotron at 48.5 MeV); or - a cyclotron in a separate vault with a beamline feeding one or more therapy rooms with rotating isocentric gantries. This type of facility has been built commercially, e.g. a 60 MeV system by Scanditronix. Like X-ray therapy, future develop­ ments in this field depend on reduc­ ing the cost of therapy systems and providing total systems suitable for hospital environments with limited technical and engineering resources. Layout of a neutron therapy centre CERN Courier, July/August 1995 Medical applications To be clinically effective, energies of several ion cyclotron for cancer therapy. This fixed hundred MeV are required for proton therapy. energy isochronous cyclotron's magnet system Pioneering projects had to work with complex, is optimized for high magnetic field but is still inadequate equipment originally intended for small enough to be installed in a hospital; it nuclear physics research, but recently a can deliver beams of up to 1.5 microamps for number of specialist organizations and treating certain categories of tumours. commercial companies have been working on dedicated systems for proton therapy. (From IBA, Louvain-la-Neuve, Belgium) This is an artist's view of a 235 MeV negative As with other therapy methods, the accelerator is only one component, and it is important that manufacturers are able to offer integrated medical service systems From Rudi Riesler, University of Washington, Seattle, USA Proton therapy deal radiotherapy deposits a large amount of energy in the tumour volume, and none in the surrounding healthy tissues. Proton therapy comes closer to this goal because of a greater concentration of dose, well defined proton ranges and points of energy release which are precisely known - the Bragg peak1. In the past, the development of deliver beams of up to 1.5 microamps, cyclotron, the beamline and the clinical proton therapy has been but with a hardware limitation to restrict gantry optics; hampered by complexity, size, and the maximum possible dose; - a safety management system, cost. To be clinically effective, ener­ - variable energy beam (235 to independent of the control system, gies of several hundred MeV are 70 MeV ) with energy spread and using hardwired interlocks and required; these were previously emittance verification; independent programmable logic unavailable for hospital installations, - a beam transport and switching controllers; and pioneering institutions had to system to connect the exit of the - a robotic patient positioning work with complex, inadequate energy selection system to the system, with monitoring equipment equipment originally intended for entrances of a number of gantries completely surrounding the patient. nuclear physics research. and fixed beamlines. Along the A few companies have proposed Recently a number of specialist beam transport system, the beam other systems, which may differ in organizations and commercial compa­ characteristics are monitored with concept designs for the gantries, nies
Load more

Recommended publications
  • Understanding the Potentiality of Accelerator
    Bortolussi et al. Radiation Oncology (2017) 12:130 DOI 10.1186/s13014-017-0860-6 RESEARCH Open Access Understanding the potentiality of accelerator based-boron neutron capture therapy for osteosarcoma: dosimetry assessment based on the reported clinical experience Silva Bortolussi1,2* , Ian Postuma2, Nicoletta Protti2, Lucas Provenzano3,4, Cinzia Ferrari5,2, Laura Cansolino5,6, Paolo Dionigi5,6, Olimpio Galasso7, Giorgio Gasparini7, Saverio Altieri1,2, Shin-Ichi Miyatake8 and Sara J. González3,4 Abstract Background: Osteosarcoma is the most frequent primary malignant bone tumour, and its incidence is higher in children and adolescents, for whom it represents more than 10% of solid cancers. Despite the introduction of adjuvant and neo-adjuvant chemotherapy that markedly increased the success rate in the treatment, aggressive surgery is still needed and a considerable percentage of patients do not survive due to recurrences or early metastases. Boron Neutron Capture Therapy (BNCT), an experimental radiotherapy, was investigated as a treatment that could allow a less aggressive surgery by killing infiltrated tumour cells in the surrounding healthy tissues. BNCT requires an intense neutron beam to ensure irradiation times of the order of 1 h. In Italy, a Radio Frequency Quadrupole (RFQ) proton accelerator has been designed and constructed for BNCT, and a suitable neutron spectrum was tailored by means of Monte Carlo calculations. This paper explores the feasibility of BNCT to treat osteosarcoma using this neutron source based on accelerator. Methods: The therapeutic efficacy of BNCT was analysed evaluating the dose distribution obtained in a clinical case of femur osteosarcoma. Mixed field dosimetry was assessed with two different formalisms whose parameters were specifically derived from radiobiological experiments involving in vitro UMR-106 osteosarcoma cell survival assays and boron concentration assessments in an animal model of osteosarcoma.
    [Show full text]
  • Proton Stereotactic Body Radiation Therapy for Liver Metastases— Results of 5-Year Experience for 81 Hepatic Lesions
    1760 Original Article Proton stereotactic body radiation therapy for liver metastases— results of 5-year experience for 81 hepatic lesions Alex R. Coffman1, Daniel C. Sufficool2, Joseph I. Kang1, Chung-Tsen Hsueh3, Sasha Swenson4, Patrick Q. McGee4, Gayathri Nagaraj3, Baldev Patyal1, Mark E. Reeves5, Jerry D. Slater1, Gary Y. Yang1 1Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Department of Radiation Oncology, Kettering Health Network, Kettering, OH, USA; 3Department of Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; 4Loma Linda University School of Medicine, Loma Linda, CA, USA; 5Department of Surgical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA Contributions: (I) Conception and design: GY Yang; (II) Administrative support: B Patyal, JD Slater, GY Yang; (III) Provision of study materials or patients: CT Hsueh, G Nagaraj, ME Reeves; (IV) Collection and assembly of data: AR Coffman, GY Yang; (V) Data analysis and interpretation: AR Coffman, GY Yang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Alex R. Coffman, MD. Department of Radiation Oncology, Loma Linda University Medical Center, 11234 Anderson Street, Suite B121, Loma Linda, CA 92354, USA. Email: [email protected]. Background: To report on our institutional experience using Proton stereotactic body radiation therapy (SBRT) for patients with liver metastases. Methods: All patients with liver metastases treated with Proton SBRT between September 2012 and December 2017 were retrospectively analyzed. Local control (LC) and overall survival (OS) were estimated using the Kaplan-Meier method calculated from the time of completion of Proton SBRT. LC was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1).
    [Show full text]
  • An Analysis of Vertebral Body Growth After Proton Beam Therapy for Pediatric Cancer
    cancers Article An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer Keiichiro Baba 1, Masashi Mizumoto 1,* , Yoshiko Oshiro 1,2, Shosei Shimizu 1 , Masatoshi Nakamura 1, Yuichi Hiroshima 1 , Takashi Iizumi 1, Takashi Saito 1, Haruko Numajiri 1, Kei Nakai 1 , Hitoshi Ishikawa 1,3, Toshiyuki Okumura 1, Kazushi Maruo 4 and Hideyuki Sakurai 1 1 Proton Medical Research Center, Department of Radiation Oncology, University of Tsukuba Hospital, Tsukuba, Ibaraki 305-8576, Japan; [email protected] (K.B.); [email protected] (Y.O.); [email protected] (S.S.); [email protected] (M.N.); [email protected] (Y.H.); [email protected] (T.I.); [email protected] (T.S.); [email protected] (H.N.); [email protected] (K.N.); [email protected] (H.I.); [email protected] (T.O.); [email protected] (H.S.) 2 Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki 305-8558, Japan 3 National Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba 263-8555, Japan 4 Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-29-853-7100; Fax: +81-29-853-7102 Simple Summary: Radiotherapy has a key role in treatment of pediatric cancer and has greatly improved survival in recent years. However, vertebrae are often included in the irradiated area, and this may affect growth after treatment.
    [Show full text]
  • Particle Accelerators and Detectors for Medical Diagnostics and Therapy Arxiv:1601.06820V1 [Physics.Med-Ph] 25 Jan 2016
    Particle Accelerators and Detectors for medical Diagnostics and Therapy Habilitationsschrift zur Erlangung der Venia docendi an der Philosophisch-naturwissenschaftlichen Fakult¨at der Universit¨atBern arXiv:1601.06820v1 [physics.med-ph] 25 Jan 2016 vorgelegt von Dr. Saverio Braccini Laboratorium f¨urHochenenergiephysik L'aspetto pi`uentusiasmante della scienza `eche essa incoraggia l'uomo a insistere nei suoi sogni. Guglielmo Marconi Preface This Habilitation is based on selected publications, which represent my major sci- entific contributions as an experimental physicist to the field of particle accelerators and detectors applied to medical diagnostics and therapy. They are reprinted in Part II of this work to be considered for the Habilitation and they cover original achievements and relevant aspects for the present and future of medical applications of particle physics. The text reported in Part I is aimed at putting my scientific work into its con- text and perspective, to comment on recent developments and, in particular, on my contributions to the advances in accelerators and detectors for cancer hadrontherapy and for the production of radioisotopes. Dr. Saverio Braccini Bern, 25.4.2013 i ii Contents Introduction 1 I 5 1 Particle Accelerators and Detectors applied to Medicine 7 2 Particle Accelerators for medical Diagnostics and Therapy 23 2.1 Linacs and Cyclinacs for Hadrontherapy . 23 2.2 The new Bern Cyclotron Laboratory and its Research Beam Line . 39 3 Particle Detectors for medical Applications of Ion Beams 49 3.1 Segmented Ionization Chambers for Beam Monitoring in Hadrontherapy 49 3.2 Proton Radiography with nuclear Emulsion Films . 62 3.3 A Beam Monitor Detector based on doped Silica Fibres .
    [Show full text]
  • Nuclear Data for Medical Applications ° ° INM-5: Nuklearchemie,INM-5: Forschungszentrum Germjülich, Abteilung Nuklearchemie, Zu Germanuniversitätköln, ° Syed M
    Mitglied der Helmholtz-Gemeinschaft derMitglied Nuclear Data for Medical Applications ° Syed M. Qaim ° INM-5: Nuklearchemie, Forschungszentrum Jülich, Germany; ° Abteilung Nuklearchemie, Universität zu Köln, Germany Plenary Lecture given at a Workshop in the 7 th Framework Programme of the European Union on “Solving Challenges in Nuclear Data for the Safety of Nuclear Facilities (CHANDA)”, Paul Scherrer Institute, Villigen, Switzerland, 23 to 25 November 2015 Outline ° Introduction - external radiation therapy - internal radionuclide applications ° Commonly used radionuclides - status of nuclear data - alternative routes for production of 99m Tc - standardisation of production data ° Research oriented radionuclides - non-standard positron emitters - novel therapeutic radionuclides ° New directions in radionuclide applications ° Future data needs ° Summary and conclusions Nuclear Data Research for Medical Use Aim ° Provide fundamental database for - external radiation therapy - internal radionuclide applications Areas of Work ° Experimental measurements ° Nuclear model calculations ° Standardisation and evaluation of existing data Considerable effort is invested worldwide in nuclear data research External Radiation Therapy • Biological changes under the impact of radiation • Of significance is linear energy transfer (LET) to tissue Types of Therapy • Photon therapy : use of 60 Co or linear accelerator (low-LET radiation ) most common • Fast neutron therapy : accelerator with E p or E d above 50 MeV (high-LET radiation ) being abandoned
    [Show full text]
  • Proton Therapy ACKNOWLEDGEMENTS
    AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumor research. For over 40 years, the Chicago-based ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care. To learn more about the ABTA, visit www.abta.org. We gratefully acknowledge Anita Mahajan, Director of International Development, MD Anderson Proton Therapy Center, director, Pediatric Radiation Oncology, co-section head of Pediatric and CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center; Kevin S. Oh, MD, Department of Radiation Oncology, Massachusetts General Hospital; and Sridhar Nimmagadda, PhD, assistant professor of Radiology, Medicine and Oncology, Johns Hopkins University, for their review of this edition of this publication. This publication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. Inclusion in this publication is not a recommendation of any product, treatment, physician or hospital. COPYRIGHT © 2015 ABTA REPRODUCTION WITHOUT PRIOR WRITTEN PERMISSION IS PROHIBITED AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy INTRODUCTION Brain tumors are highly variable in their treatment and prognosis. Many are benign and treated conservatively, while others are malignant and require aggressive combinations of surgery, radiation and chemotherapy.
    [Show full text]
  • Carbon Ion Therapy for Advanced Sinonasal Malignancies: Feasibility
    Jensen et al. Radiation Oncology 2011, 6:30 http://www.ro-journal.com/content/6/1/30 RESEARCH Open Access Carbon ion therapy for advanced sinonasal malignancies: feasibility and acute toxicity Alexandra D Jensen1*, Anna V Nikoghosyan1, Swantje Ecker2, Malte Ellerbrock2, Jürgen Debus1 and Marc W Münter1 Abstract Purpose: To evaluate feasibility and toxicity of carbon ion therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field, local control hence calls for dose escalation which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon ion therapy offers the advantage of sharp dose gradients promising increased dose application without increase of side-effects. Methods: Twenty-nine patients with various sinonasal malignancies were treated from 11/2009 to 08/2010. Accompanying toxicity was evaluated according to CTCAE v.4.0. Tumor response was assessed according to RECIST. Results: Seventeen patients received treatment as definitive RT, 9 for local relapse, 2 for re-irradiation. All patients had T4 tumours (median CTV1 129.5 cc, CTV2 395.8 cc), mostly originating from the maxillary sinus. Median dose was 73 GyE mostly in mixed beam technique as IMRT plus carbon ion boost. Median follow- up was 5.1 months [range: 2.4 - 10.1 months]. There were 7 cases with grade 3 toxicity (mucositis, dysphagia) but no other higher grade acute reactions; 6 patients developed grade 2 conjunctivits, no case of early visual impairment. Apart from alterations of taste, all symptoms had resolved at 8 weeks post RT.
    [Show full text]
  • Present Status of Fast Neutron Therapy Survey of the Clinical Data and of the Clinical Research Programmes
    PRESENT STATUS OF FAST NEUTRON THERAPY SURVEY OF THE CLINICAL DATA AND OF THE CLINICAL RESEARCH PROGRAMMES Andre Wambersie and Francoise Richard Universite Catholique de Louvain, Unite de Radiotherapie, Neutron- et CurietheVapie, Cliniques Universitaires St-Luc, 1200-Brussels, Belgium. Abstract The clinical results reported from the different neutron therapy centres, in USA, Europe and Asia, are reviewed. Fast neutrons were proven to be superior to photons for locally extended inoperable salivary gland tumours. The reported overall local control rates are 67 % and 24 % respectively. Paranasal sinuses and some tumours of the head and neck area, especially extended tumours with large fixed lymph nodes, are also indications for neutrons. By contrast, the results obtained for brain tumours were, in general, disappointing. Neutrons were shown to bring a benefit in the treatment of well differentiated slowly growing soft tissue sarcomas. The reported overall local control rates are 53 % and 38 % after neutron and photon irradiation respectively. Better results, after neutron irradiation, were also reported for bone- and chondrosarcomas. The reported local control rates are 54 % for osteosarcomas and 49 % for chondrosarcomas after neutron irradiation; the corresponding values are 21 % and 33 % respectively after photon irradiation. For locally extended prostatic adenocarcinoma, the superiority of mixed schedule (neutrons + photons) was demonstrated by a RTOG randomized trial (local control rates 77% for mixed schedule compared to 31 % for photons). Neutrons were also shown to be useful for palliative treatment of melanomas. Further studies are needed in order to definitively evaluate the benefit of fast neutrons for other localisations such as uterine cervix, bladder, and rectum.
    [Show full text]
  • PIONEERING THERAPY for LIFE Table of Contents
    PIONEERING THERAPY FOR LIFE Table of contents Key figures 20151 IBA at a glance 2 IBA is 30 years old 4 Proton therapy 6 Dosimetry 20 RadioPharma Solutions 24 Industrial 26 Human resources 28 Corporate social responsibility 30 Governance 36 Economical review 39 IFRS consolidated financial statements for the year ended December 31, 2015 73 IBA SA Annual financial statements148 General information 152 Stock market and shareholders 157 Key figures 2015 REBIT (3) / SALES & SERVICES TRENDS 12% 12 IBA is a high-technology medical 10.9% company which concentrates 10% 10 its activities on proton therapy, radiopharmacy, particle accelerators 8 8% for industry, and dosimetry. 6% IBA is the worldwide leader in 6 the proton therapy market. 4 4% Listed on the NYSE Euronext Brussels. 2 2% 1 200 employees worldwide. 0% IBA operates in two areas: “Proton 0 Therapy and Other Accelerators ” and 2010 2011 2012 2013 2014 2015 “Dosimetry”. Key figures 2015 + 22.6% 332 2015 revenue increase EUR million Backlog in Proton Therapy & Other Accelerators OPERATING RESULTS 2014 2015 Change CAGR (1) (EUR 000) (EUR 000) (EUR 000) (%) 2014/2015 Sales and services 220 577 270 357 49 780 22.60% Gross margin 96 096 113 655 18.30% REBITDA (2) 28 321 33 710 5 389 19.00% REBITDA/Sales and services 12.80% 12.50% REBIT (3) 22 932 29 553 6 621 28.90% REBIT/Sales and services 10.40% 10.90% Net profit 24 294 61 189 36 895 151.90% (1) CAGR: compound annual growth rate (2) REBITDA: recurring earnings before interest, taxes, depreciation, and amortization.
    [Show full text]
  • Planning and Implementing a Swiss Radio-Oncology Network
    Chair Secretary PROTON Michael Goitein Ph. D. Daniel Miller Ph. D. THERAPY Department of Radiation Oncology Department of Radiation Medicine C O- Massachusetts General Hospital Loma Linda University Medical Center OPERATIVE Boston MA 02114 Loma Linda CA 92354 G ROUP (617) 724 - 9529 (909) 824 - 4197 (617) 724 - 9532 Fax (909) 824 - 4083 Fax ABSTRACTS of the XXIV PTCOG MEETING held in Detroit, Michigan, USA April 24-26 1996 1 INDEX Page PTCOG Focus Session I: Comparative treatment planning of nasopharyngeal tumors PTCOG nasopharynx treatment planning intercomparison. 5 A. Smith PTCOG Focus Session II: Proton theray clinical studies Proton therapy in 1996: a world wide perspective. 6 J. M. Sisterson Arteriovenous malformations: the NAC experience. 6 F. Vernimmen, J. Wilson, D. Jones, N. Schreuder, E. De Kock, J. Symons Preliminary results of carbon-ion therapy at NIRS. 6 H. Tsujii, J. Mizoe, T. Miyamoto, S. Morita, M. Mukai, T. Nakano, H. Kato, T. Kamada, K. Morita Proton radiation therapy for orbital and parameningeal rhabdomyosarcoma. 7 E. B. Hug, J.A. Adams, J. E. Munzenrider Conformal radiation therapy for retinoblastoma: comparison of various 3D proton plans. 8 M. Krengli, J. A Adams, E. B Hug PTCOG Focus Session III Radiotherapy in the treatment of prostate cancer: neutrons, protons or photons? An analysis of acute and late toxicity in a randomized study of pion vs. photon irradiation 9 for stage T3/4 prostate cancer. T. Pickles, G. Goodman, M. Dimitrov, G. Duncan, C. Fryer, P. Graham, M. McKenzie, J. Morris, D. Rheaume, I. Syndikus With conformal photon irradiation, who needs particles? 10 J.
    [Show full text]
  • Clinical Policy: Proton and Neutron Beam Therapies Reference Number: CP.MP.70 Coding Implications Last Review Date: 11/20 Revision Log
    Clinical Policy: Proton and Neutron Beam Therapies Reference Number: CP.MP.70 Coding Implications Last Review Date: 11/20 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Proton beam therapy (PBT) is a form of external beam radiation therapy (EBRT) that utilizes protons (positively charged subatomic particles) to precisely target a specific tissue mass. Proton beams can penetrate deep into tissues to reach tumors, while delivering less radiation to surrounding tissues. This may make PBT more effective for inoperable tumors, or for those areas in which damage to healthy tissue would pose an unacceptable risk. Neutron beam therapy (NBT) is a less widely available form of EBRT that utilizes neutrons. Its clinical use is very limited due to difficulties in the delivery of this treatment modality. Policy/Criteria I. It is the policy of health plans affiliated with Centene Corporation® that proton beam therapy is medically necessary for the following indications: A. Ocular tumors with no distant metastasis. Fiducial markers (tantalum clips) are permitted to allow eye and tumor position verification; or B. Primary or metastatic tumors of the spine where the spinal cord tolerance may be exceeded with conventional treatment or where the spinal cord has previously been irradiated; or C. Tumors that approach or are located at the base of the skull, including but not limited to: chordoma or chondrosarcoma; or D. Primary hepatocellular cancer treated in a hypofractionated regimen; or E. Primary or benign solid tumors in members/enrollees ≤ 18 years old; or F. Genetic syndromes making total volume of radiation minimization crucial such as but not limited to NF-1 patients and retinoblastoma; or G.
    [Show full text]
  • Clinical Progress in Proton Radiotherapy: Biological Unknowns
    cancers Review Clinical Progress in Proton Radiotherapy: Biological Unknowns Laura Vanderwaeren 1,2,3 , Rüveyda Dok 1, Kevin Verstrepen 2,3 and Sandra Nuyts 1,4,* 1 Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium; [email protected] (L.V.); [email protected] (R.D.) 2 Laboratory of Genetics and Genomics, Centre for Microbial and Plant Genetics, KU Leuven, 3000 Leuven, Belgium; [email protected] 3 Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3000 Leuven, Belgium 4 Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium * Correspondence: [email protected]; Tel.: +32-1634-7600; Fax: +32-1634-7623 Simple Summary: Proton radiation therapy is a more recent type of radiotherapy that uses proton beams instead of classical photon or X-rays beams. The clinical benefit of proton therapy is that it allows to treat tumors more precisely. As a result, proton radiotherapy induces less toxicity to healthy tissue near the tumor site. Despite the experience in the clinical use of protons, the response of cells to proton radiation, the radiobiology, is less understood. In this review, we describe the current knowledge about proton radiobiology. Abstract: Clinical use of proton radiation has massively increased over the past years. The main reason for this is the beneficial depth-dose distribution of protons that allows to reduce toxicity to normal tissues surrounding the tumor. Despite the experience in the clinical use of protons, the radiobiology after proton irradiation compared to photon irradiation remains to be completely elucidated. Proton radiation may lead to differential damages and activation of biological processes.
    [Show full text]